Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 31;14(1):11-15.
doi: 10.21037/tcr-24-1813. Epub 2025 Jan 7.

Navigating restriction from interstitial lung disease (ILD) with stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer: soaring beyond the current treatment paradigm

Ari A Kassardjian  1 , Jyoti Malhotra  2 , Percy Lee  3
Affiliations
Editorial

Navigating restriction from interstitial lung disease (ILD) with stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer: soaring beyond the current treatment paradigm

Ari A Kassardjian et al. Transl Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); interstitial lung disease (ILD); stereotactic ablative radiotherapy (SABR); stereotactic body radiotherapy (SBRT).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1813/coif). P.L. has received consulting fees from Varian, ViewRay, AstraZeneca, Genentech, Johnson & Johnson, Roche, and RTOG foundation, honoraria for presentations from Varian, ViewRay, and AstraZeneca, support for attending meetings from Radiosurgery Society, participated in data safety monitoring boards for Genentech, ViewRay, AstraZeneca, and Roche, and served a leadership or fiduciary role as Radiosurgery Society Board of Director, Radiosurgery Society Treasurer, and with ASTRO. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-9. 10.1016/S0360-3016(99)00183-2 - DOI - PubMed
    1. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444-50. 10.1016/j.ijrobp.2012.04.043 - DOI - PMC - PubMed
    1. Kraus KM, Simonetto C, Kundrát P, et al. Potential Morbidity Reduction for Lung Stereotactic Body Radiation Therapy Using Respiratory Gating. Cancers (Basel) 2021;13:5092. 10.3390/cancers13205092 - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: non-small cell lung cancer. version 7.2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf - PubMed
    1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. 10.1001/jama.2010.261 - DOI - PMC - PubMed

LinkOut - more resources